Antidiabetic Treatment before Hospitalization and Admission Parameters in Patients with Type 2 Diabetes, Obesity, and SARS-CoV-2 Viral Infection

• Published in: Journal of personalized medicine 2023-02, Vol.13 (3), p.392
• Main Authors: Reștea, Patricia-Andrada, Mureșan, Mariana, Voicu, Adrian, Jurca, Tunde, Pallag, Annamaria, Marian, Eleonora, Vicaș, Laura Grațiela, Jeican, Ionuț I, Crivii, Carmen-Bianca
• Format: Article
• Language: English
• Subjects: Analysis; Care and treatment; Comorbidity; Congestive heart failure; Coronaviruses; COVID-19; Cytokine storm; Diabetes mellitus (non-insulin dependent); Diabetes therapy; Diabetics; Health aspects; Heart diseases; Hypertension; Infection; Insulin; Insulin resistance; Ischemia; Medical research; Medicine, Experimental; Metformin; Morbidity; Mortality; Obesity; Patients; Precision medicine; Procalcitonin; Romania; Severe acute respiratory syndrome coronavirus 2; Type 2 diabetes; Viral infections
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm13030392

SARS-CoV-2 viral infection is a current and important topic for patients with comorbidities of type 2 diabetes and obesity, associated with increased risk of mortality and morbidity. This study aims to analyze, compare and describe admission parameters in patients with type 2 diabetes, obesity, and SARS-CoV-2 infection based on whether they received insulin therapy before hospital admission. Our study enrolled patients diagnosed with type 2 diabetes, obesity, and SARS-CoV-2 viral infection, 81 patients without insulin treatment before hospital admission, and 81 patients with insulin at "Gavril Curteanu" Municipal Clinical Hospital of Oradea, Romania, between August 2020 and March 2022. RT-PCR/rapid antigen tests were used for detecting SARS-CoV-2 viral infection. The severe form of COVID-19 was found in 66% of all patients (65% in the group without insulin and 67% in the group with insulin). Oxygen saturation at the time of hospital admission was greater or equal to 90% in 62% of all patients. The most associated comorbidities we founded in this study were: hypertension in 75% of all patients (grade two hypertension 63% in the group without insulin and 64% in the group with insulin), ischemic heart disease in 35% of patients (25% in the group without insulin and 44% in the group with insulin, = 0.008), heart failure in 9.3% of all patients (8.6% in the group without insulin and 10% in the group with insulin). CRP and procalcitonin are increased in both groups at hospital admission, with a slightly higher trend in the group with insulin therapy before hospital admission. We found that 56% of patients in the group with insulin treatment were with uncontrolled diabetes on admission. Only 10% of patients required a change in antidiabetic treatment with insulin therapy at discharge. In our study, 89% of all patients did not require short-term home oxygen therapy at discharge. Antidiabetic therapy taken before hospital admission did not protect patients against cytokine storm in COVID-19, but is very important in the pathophysiological stage of comorbidities. Paraclinical parameters at hospitalization showed differences in correlation with oral antidiabetic treatment like metformin or insulin therapy. Changing the antidiabetic treatment for a small percentage of patients in the group who had not been receiving insulin therapy before discharge was necessary. It is necessary for future studies to see all changes involved in antidiabetic treatment in patients with